Background: Chimeric antigen receptor (CAR)-modified T cells have successfully harnessed T cell immunity against malignancies, but they are by no means the only cell therapies in development for cancer. Main Text Summary: Systemic immunity is thought to play a key role in combatting neoplastic disease; in this vein, genetic modifications meant to explore other components of T cell immunity are being evaluated. In addition, other immune cells-from both the innate and adaptive compartments-are in various stages of clinical application. In this review, we focus on these non-CAR T cell immunotherapeutic approaches for malignancy. The first section describes engineering T cells to express non-CAR constructs, and the second section describes other gene-modified cells used to target malignancy. Conclusions: CAR T cell therapies have demonstrated the clinical benefits of harnessing our body's own defenses to combat tumor cells. Similar research is being conducted on lesser known modifications and gene-modified immune cells, which we highlight in this review.
CITATION STYLE
Patel, S., Burga, R. A., Powell, A. B., Chorvinsky, E. A., Hoq, N., McCormack, S. E., … Cruz, C. R. Y. (2019). Beyond CAR T cells: Other cell-based immunotherapeutic strategies against cancer. Frontiers in Oncology, 9(APR). https://doi.org/10.3389/fonc.2019.00196
Mendeley helps you to discover research relevant for your work.